Business Context and Reporting Period
Company: Dermata Therapeutics, Inc. (DRMA)
Filing Type: Form 10-Q (Unaudited)
Period Ended: March 31, 2026
Business Overview: In September 2025, the Company executed a strategic pivot from developing prescription drug candidates to becoming a science-driven leader in direct-to-consumer (DTC) dermatologic solutions. The Company anticipates launching its first DTC product, the "Foundational Treatment" under the Tome skincare line, in mid-2026. The Company is classified as a smaller reporting company and an emerging growth company.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(1,847,706) | $(2,303,587) |
| Net Loss Per Share (Basic & Diluted) | $(0.48) | $(4.47) |
| Total Operating Expenses | $1,926,382 | $2,339,803 |
| Research & Development (R&D) | $383,724 | $1,281,141 |
| Selling, General & Administrative (SG&A) | $1,542,658 | $1,058,662 |
| Interest Income | $78,676 | $36,216 |
| Cash and Cash Equivalents (End of Period) | $6,945,282 | $9,719,268 |
| Net Cash Used in Operating Activities | $(2,479,718) | $(1,934,066) |
| Net Cash Provided by Financing Activities | $1,903,022 | $8,491,764 |
| Accumulated Deficit | $(75,081,602) | $(67,978,926) |
Material Changes vs. Prior Period
- Reduced R&D Spend: R&D expenses decreased by approximately $0.9 million (70%) compared to Q1 2025. This reduction is primarily due to the completion of the Phase 3 STAR-1 clinical trial for the former prescription candidate XYNGARI in Q2 2025 and the strategic shift away from prescription development.
- Increased SG&A: SG&A expenses increased by approximately $0.5 million (46%) compared to Q1 2025. The increase is driven by $0.2 million in marketing expenses for the upcoming Tome launch, higher audit fees, and increased legal fees.
- Improved Net Loss: Net loss narrowed by approximately $0.46 million, largely due to the significant reduction in clinical trial costs, partially offset by higher marketing and administrative expenses.
- Capital Raise: In Q1 2026, the Company raised approximately $2.0 million in net proceeds through its At-The-Market (ATM) offering, exhausting the remaining capacity under the agreement. In contrast, Q1 2025 saw significant financing activity including a PIPE and warrant inducement totaling over $8.5 million in net financing cash flow.
- Inventory Build: The Company recorded $93,091 in inventory (raw materials) as of March 31, 2026, compared to zero in the prior period, reflecting preparation for the mid-2026 product launch.
Guidance, Outlook, Risks, and Contingencies
- Going Concern: The Company has raised substantial doubt about its ability to continue as a going concern for the 12-month period following the filing date. With cash of approximately $6.9 million, management expects to fund operations into the first quarter of 2027. Additional capital will be required to sustain operations and support the product launch.
- Product Launch: The Company plans to launch its first DTC product, the Tome Foundational Treatment, in mid-2026. Future cash burn is expected to increase due to marketing, branding, and launch event expenses.
- Legal Proceedings (Villani, Inc.): On April 23, 2026, Villani, Inc. filed a lawsuit alleging false advertising, breach of contract, and conversion regarding the Company's Spongilla-based products. On May 6, 2026, the court granted a partial Temporary Restraining Order (TRO) limiting specific advertising claims. A hearing for a preliminary injunction is scheduled for July 14, 2026. The Company disputes the allegations.
- Supply Chain Risk: The Company relies on a single supplier, Reka-Farm (a Russian entity), for its key raw material, Spongilla. While the Company has sufficient inventory for the initial launch, future supply could be disrupted by sanctions or export controls related to the war in Ukraine.
- License Termination: The Company terminated its license agreement with Villani, Inc. effective February 15, 2026, following a dispute over the strategic pivot to DTC products. No payments have been accrued as the Company believes obligations are fulfilled.
Investor Verification Checklist
- Cash Runway: Verify the accuracy of the "first quarter of 2027" cash runway estimate given the anticipated increase in marketing spend for the mid-2026 launch.
- Legal Impact: Monitor the outcome of the Villani, Inc. lawsuit and the potential scope of the preliminary injunction, which could restrict marketing claims or product sales.
- Supply Chain Continuity: Assess the risk of sanctions on the Russian supplier (Reka-Farm) and the feasibility/cost of alternative sourcing for Spongilla raw materials.
- Capital Requirements: Evaluate the likelihood and terms of future equity or debt financing needed to bridge the gap between current cash reserves and the revenue generation from the Tome launch.
- Warrant Dilution: Note the significant number of outstanding warrants (5.4 million shares) with varying exercise prices, many of which are subject to shareholder approval for exercise.